Glutamate-based therapeutic approaches: inhibitors of glycine transport.

[1]  R. Steinberg,et al.  2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission , 2006, Neuroscience.

[2]  R. Depoortère,et al.  Neurochemical, Electrophysiological and Pharmacological Profiles of the Selective Inhibitor of the Glycine Transporter-1 SSR504734, a Potential New Type of Antipsychotic , 2005, Neuropsychopharmacology.

[3]  J. Lowe.  Novel inhibitors of the type 1 transporter for glycine (GlyT1) as antipsychotic agents , 2005 .

[4]  H. Betz,et al.  Glycine transporters: essential regulators of neurotransmission. , 2005, Trends in biochemical sciences.

[5]  B. López-Corcuera,et al.  Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion. , 2005, Trends in pharmacological sciences.

[6]  D. Javitt,et al.  Modulation of Striatal Dopamine Release by Glycine Transport Inhibitors , 2005, Neuropsychopharmacology.

[7]  B. Cubelos,et al.  Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. , 2005, Cerebral cortex.

[8]  D. Javitt,et al.  Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action , 2005, Molecular Psychiatry.

[9]  K. Vogt,et al.  Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression , 2004, Neuroscience Letters.

[10]  P. Mallorga,et al.  Effects of typical and atypical antipsychotics on human glycine transporters , 2004, Schizophrenia Research.

[11]  D. Javitt,et al.  Glutamate as a therapeutic target in psychiatric disorders , 2004, Molecular Psychiatry.

[12]  R. Lim,et al.  Blockade of glycine transporter-1 (GLYT-1) potentiates NMDA receptor-mediated synaptic transmission in hypoglossal motorneurons. , 2004, Journal of neurophysiology.

[13]  C. Christoffersen,et al.  The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[14]  J. Trouslard,et al.  Role of glial and neuronal glycine transporters in the control of glycinergic and glutamatergic synaptic transmission in lamina X of the rat spinal cord , 2004, The Journal of physiology.

[15]  S. B. Caine,et al.  Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Sur,et al.  The therapeutic potential of glycine transporter-1 inhibitors , 2004, Expert opinion on investigational drugs.

[17]  Nicholas Lange,et al.  Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia , 2004, Biological Psychiatry.

[18]  A. Slassi,et al.  Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases , 2004 .

[19]  D. Javitt,et al.  Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis , 2004, Schizophrenia Research.

[20]  Shan Xie,et al.  Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists , 2004, Neuropsychopharmacology.

[21]  D. Javitt,et al.  High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia , 2004, Biological Psychiatry.

[22]  A. Lajtha,et al.  Antagonism of phencyclidine-induced hyperactivity by glycine in mice , 1986, Neurochemical Research.

[23]  D. Attwell,et al.  Active release of glycine or d‐serine saturates the glycine site of NMDA receptors at the cerebellar mossy fibre to granule cell synapse , 2003, The European journal of neuroscience.

[24]  D. Richter,et al.  Inactivation of the Glycine Transporter 1 Gene Discloses Vital Role of Glial Glycine Uptake in Glycinergic Inhibition , 2003, Neuron.

[25]  D. Richter,et al.  Deletion of the Mouse Glycine Transporter 2 Results in a Hyperekplexia Phenotype and Postnatal Lethality , 2003, Neuron.

[26]  P. Mallorga,et al.  Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4′-fluorophenyl)-3-(4′phenylphenoxy)propyl])sarcosine , 2003, Neuropharmacology.

[27]  P. Mallorga,et al.  The Glycine Transporter Type 1 Inhibitor N-[3-(4′-Fluorophenyl)-3-(4′-Phenylphenoxy)Propyl]Sarcosine Potentiates NMDA Receptor-Mediated Responses In Vivo and Produces an Antipsychotic Profile in Rodent Behavior , 2003, The Journal of Neuroscience.

[28]  É. Schmidt,et al.  The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study , 2003, Pharmacology Biochemistry and Behavior.

[29]  Charles R. Yang,et al.  Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. , 2003, Journal of neurophysiology.

[30]  D. Javitt,et al.  Subchronic Continuous Phencyclidine Administration Potentiates Amphetamine-Induced Frontal Cortex Dopamine Release , 2003, Neuropsychopharmacology.

[31]  M. Millan.  N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. , 2002, Current drug targets. CNS and neurological disorders.

[32]  A. Phillips,et al.  Glutamate Receptor-Dependent Modulation of Dopamine Efflux in the Nucleus Accumbens by Basolateral, But Not Central, Nucleus of the Amygdala in Rats , 2002, The Journal of Neuroscience.

[33]  R. Vandenberg,et al.  N[3‐(4′‐fluorophenyl)‐3‐(4′‐phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport , 2001, British journal of pharmacology.

[34]  D. Javitt,et al.  Adjunctive high-dose glycine in the treatment of schizophrenia. , 2001, The international journal of neuropsychopharmacology.

[35]  V. Ognyanov,et al.  ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. , 2001, Molecular pharmacology.

[36]  G. Walker,et al.  Discovery and SAR of org 24598-a selective glycine uptake inhibitor. , 2001, Bioorganic & medicinal chemistry letters.

[37]  M. Laruelle,et al.  Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia , 2000, Biological Psychiatry.

[38]  J. Coyle,et al.  D-serine added to clozapine for the treatment of schizophrenia. , 1999, The American journal of psychiatry.

[39]  J. Newcomer,et al.  NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.

[40]  S. Potkin,et al.  Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. , 1999, The American journal of psychiatry.

[41]  J. Coyle,et al.  Modulation of N-methyl-D-aspartate receptor function by glycine transport. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[43]  D. Javitt,et al.  Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. , 1998, The international journal of neuropsychopharmacology.

[44]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[45]  J. Morrow,et al.  Molecular cloning and functional expression of the human glycine transporter GlyT2 and chromosomal localisation of the gene in the human genome 1 , 1998 .

[46]  N. Nelson,et al.  The Family of Na+/Cl− Neurotransmitter Transporters , 1998, Journal of neurochemistry.

[47]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[48]  A. Lajtha,et al.  Reversal of Phencyclidine-Induced Hyperactivity by Glycine and the Glycine Uptake Inhibitor Glycyldodecylamide , 1997, Neuropsychopharmacology.

[49]  C. Bergman,et al.  Control of NMDA Receptor Activation by a Glycine Transporter Co-Expressed in Xenopus Oocytes , 1997, The Journal of Neuroscience.

[50]  D. Javitt,et al.  Double-Blind, Placebo-Controlled, Crossover Trial of Glycine Adjuvant Therapy for Treatment-Resistant Schizophrenia , 1996, British Journal of Psychiatry.

[51]  J. Gomeza,et al.  Regional Distribution and Developmental Variation of the Glycine Transporters GLYT1 and GLYT2 in the Rat CNS , 1995, The European journal of neuroscience.

[52]  J. Storm-Mathisen,et al.  Glycine transporters are differentially expressed among CNS cells , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[53]  D. Javitt,et al.  Amelioration of negative symptoms in schizophrenia by glycine. , 1994, The American journal of psychiatry.

[54]  S. Kingsmore,et al.  Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. , 1994, Molecular pharmacology.

[55]  B. Borowsky,et al.  Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene , 1993, Neuron.

[56]  D. Javitt,et al.  Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.

[57]  H. Betz.  Ligand-gated ion channels in the brain: The amino acid receptor superfamily , 1990, Neuron.